Search Results - L. Austin Doyle

Refine Results
  1. 1
    A multidrug resistance transporter from human MCF-7 breast cancer cells

    A multidrug resistance transporter from human MCF-7 breast cancer cells by L. Austin Doyle, Weidong Yang, Lynne V. Abruzzo, Tammy Krogmann, Yongming Gao, Arun K. Rishi, Douglas D. Ross

    Published 1998
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma

    Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma by Carla M. Prado, Tanios Bekaii‐Saab, L. Austin Doyle, Sharad Shrestha, Sunita Ghosh, Vickie E. Baracos, Michael B. Sawyer

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures

    Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures by Vivek Subbiah, Aung Naing, Robert Brown, Helen Chen, L. Austin Doyle, Patricia LoRusso, Robert S. Benjamin, Pete Anderson, Razelle Kurzrock

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway

    Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway by Naifa L. Busaidy, Azeez Farooki, Afshin Dowlati, John P. Perentesis, Janet Dancey, L. Austin Doyle, Joanna M. Brell, Lillian L. Siu

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma

    Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma by Aung Naing, Patricia LoRusso, Siqing Fu, David S. Hong, H. X. Chen, L. Austin Doyle, Alexandria T. Phan, Mouhammed Amir Habra, Razelle Kurzrock

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival

    High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival by King F. Kwong, Martin J. Edelman, Mohan Suntharalingam, Lindsay B. Cooper, Ziv Gamliel, W. Burrows, P Hausner, L. Austin Doyle, Mark J. Krasna

    Published 2005
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group

    Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology gr... by Lars M. Wagner, Maryam Fouladi, Atif Ahmed, Mark Krailo, Brenda J. Weigel, Steven G. DuBois, L. Austin Doyle, Helen Chen, Susan M. Blaney

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors

    Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors by Aung Naing, Patricia LoRusso, Siqing Fu, David S. Hong, Pete Anderson, Robert S. Benjamin, Joseph A. Ludwig, Helen X. Chen, L. Austin Doyle, Razelle Kurzrock

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Atypical Multidrug Resistance: Breast Cancer Resistance Protein Messenger RNA Expression in Mitoxantrone-Selected Cell Lines

    Atypical Multidrug Resistance: Breast Cancer Resistance Protein Messenger RNA Expression in Mitoxantrone-Selected Cell Lines by D D Ross, Weidong Yang, Lynne V. Abruzzo, William S. Dalton, E Schneider, Hermann Lage, Manfred Dietel, Lee M. Greenberger, Susan P.C. Cole, L. Austin Doyle

    Published 1999
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer

    Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer by T. Khanh, Giovanna Speranza, Rachel Bishop, Sonny Khin, Larry Rubinstein, Robert J. Kinders, Manuel B. Datiles, Michelle Eugeni, Michael Lam, L. Austin Doyle, James H. Doroshow, Shivaani Kummar

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium

    Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium by Sonali M. Smith, Koen van Besien, Theodore Karrison, Janet Dancey, Peter McLaughlin, Anas Younes, Scott E. Smith, Patrick J. Stiff, Eric P. Lester, Sanjiv Modi, L. Austin Doyle, Everett E. Vokes, Barbara Pro

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer

    Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer by Aung Naing, Razelle Kurzrock, Angelika M. Burger, Sachin Gupta, Xiudong Lei, Naifa L. Busaidy, David S. Hong, Helen X. Chen, L. Austin Doyle, Lance K. Heilbrun, Eric Rohren, Chaan S. Ng, Chandtip Chandhasin, Patricia LoRusso

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours

    A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours by Breelyn A. Wilky, Michelle A. Rudek, Shabina Roohi Ahmed, Dan Laheru, David Cosgrove, Ross C. Donehower, Barry D. Nelkin, Douglas W. Ball, L. Austin Doyle, H Chen, X Ye, Graham Bigley, Chris Womack, Nilofer S. Azad

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks

    Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks by Jann N. Sarkaria, E. Galanis, Wenting Wu, Allan B. Dietz, Timothy J. Kaufmann, Michael P. Gustafson, Paul D. Brown, Joon H. Uhm, Ravi D. Rao, L. Austin Doyle, Caterina Giannini, Kurt A. Jaeckle, Jan C. Buckner

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    A Phase I Study of Dinaciclib in Combination With MK‐2206 in Patients With Advanced Pancreatic Cancer

    A Phase I Study of Dinaciclib in Combination With MK‐2206 in Patients With Advanced Pancreatic Cancer by Adrian Murphy, Marianna Zahurak, Mirat Shah, Colin D. Weekes, Aaron R. Hansen, Lillian L. Siu, Anna Spreafico, Noelle K. LoConte, Nicole M. Anders, T. Miles, Michelle A. Rudek, L. Austin Doyle, Barry D. Nelkin, Anirban Maitra, Nilofer S. Azad

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia

    Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia by Judith E. Karp, Amanda L. Blackford, B. Douglas Smith, Katrina Alino, Amy Hatfield Seung, Javier Bolaños‐Meade, Jacqueline M. Greer, Hetty E. Carraway, Steven D. Gore, Richard J. Jones, Mark J. Levis, Michael A. McDevitt, L. Austin Doyle, James R. Wright

    Published 2009
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy

    Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy by Vincent Chung, Shannon McDonough, Philip A. Philip, Dana B. Cardin, Andrea Wang‐Gillam, Laifong Hui, Mohamedtaki Abdulaziz Tejani, Tara Elisabeth Seery, Irene Dy, Tareq Al Baghdadi, Andrew Hendifar, L. Austin Doyle, Andrew M. Lowy, Katherine A. Guthrie, Charles D. Blanke, Howard S. Höchster

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia

    Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia by Jonathan Webster, Raoul Tibes, Larry Morris, Amanda L. Blackford, Mark R. Litzow, Mrinal M. Patnaik, Gary L. Rosner, Ivana Gojo, Robert J. Kinders, Lihua Wang, L. Austin Doyle, Catherine J. Huntoon, Larry M. Karnitz, Scott H. Kaufmann, Judith E. Karp, B. Douglas Smith

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers

    Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers by Tanios Bekaii‐Saab, Mitch A. Phelps, Xiaobai Li, Motoyasu Saji, Laura W. Goff, John Kauh, Bert H. O’Neil, Stephanie Balsom, Catherine Balint, R. Liersemann, Vasily Vasko, Mark Bloomston, W. Marsh, L. Austin Doyle, Gilian Ellison, Michael R. Grever, Matthew D. Ringel, Miguel A. Villalona‐Calero

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias

    Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias by Judith E. Karp, Benjamin D. Smith, Linda Resar, Jacqueline M. Greer, Amanda L. Blackford, Ming Zhao, Dwella Moton-Nelson, Katrina Alino, Mark J. Levis, Steven D. Gore, Biju Joseph, Hetty E. Carraway, Michael A. McDevitt, Lorena Bagain, Karen Mackey, Janet Briel, L. Austin Doyle, James R. Wright, Michelle A. Rudek

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: